Anteris Technologies Soars 42.58% on DurAVR® Milestone

Anteris Technologies' stock surged 42.58% in pre-market trading on April 1, 2025, driven by significant clinical milestones achieved with its DurAVR® Transcatheter Heart Valve (THV).

The company announced that its DurAVR® THV has been used to treat over 100 patients worldwide, marking a major achievement in the clinical development of the biomimetic valve. This milestone includes a diverse range of patients, such as those with de novo aortic stenosis, valve-in-valve (ViV) patients, and complex anatomies like bicuspid aortic valve.

The clinical data from these 100 patients revealed a perfect safety profile, with zero cardiovascular mortality at one year. The valve demonstrated excellent hemodynamic performance, with sustained benefits and no valve-related mortality observed. This positive data supports the effectiveness of the DurAVR® THV and positions the company well for its upcoming pivotal trial, scheduled to begin in Q3 2025, pending FDA approval.

Anteris Technologies is preparing to advance its clinical programs further, with the DurAVR® THV expected to enter its registration trial later this year. The company's progress in treating heart valve disease patients with its innovative THV technology has garnered significant attention, contributing to the stock's pre-market surge.